title: FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
abstract: OBJECTIVE
  Vascular endothelial growth fac-tor (VEGF) serves as a logical target for antiangiogenic cancer therapy. This study is to investigate the inhibitory effects of FP3, a novel VEGF blocker, on angiogenesis in vitro and in vivo as well as anti-tumor effects ona liver cancer xenograft model in vivo.
  
  
  METHODS
  The inhibitory effects of FP3 on angiogenesis were assessed by using human umbilical vein endothelial cells(HUVECs) in vitro and the chick embryo chorioallantoialc membrane (CAM) in viva. The inhibitory effect of FP3 on tumor growth in viva were evaluated in a human liver cancer cell line Hep-3B xenograft model in nude mice with the methods of tumor growth regression as-say.
  
  
  RESULTS
  In experiments with HUVECs, FP3 inhibit-ed cell survival and tube formation. In CAM assay, FP3 suppressed MCF-7 human breast cancer cell-induced angiogenesis. In tumor growth regression assay, FP3 significantly blocked the growth of Hep-3B tumor cellin subcutaneous tumor xenograft model in nude mice.
  
  
  CONCLUSIONS
  FP3 has excellent inhibitory effects on angiogenesis both in vitro and in viva and antitumor effect on liver cancer xenograft model; therefore, it might be used as an effective antiangiogenic agent in treatment of liver cancer.
authors.affiliation: Department of General Surgery, Huzhou Central Hospital, Huzhou, Zhejiang, China.
authors.forename: Weili
authors.initials: W
authors.lastname: Gao
authors.forename: Ketao
authors.initials: K
authors.lastname: Jin
authors.forename: Huanrong
authors.initials: H
authors.lastname: Lan
authors.forename: Na
authors.initials: N
authors.lastname: Han
authors.forename: Feilin
authors.initials: F
authors.lastname: Cao
authors.forename: Lisong
authors.initials: L
authors.lastname: Teng
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply*; D004305:Dose-Response Relationship, Drug; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D061986:MCF-7 Cells; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; C557495:FP3 VEGF receptor Fc-fusion protein; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A